1. Scrip

SK Bioscience First To Line In Korea COVID Vaccine Race

Booster Studies Underway Amid Global Plans

 
• By Jung Won Shin

SK Bioscience has received the world’s first approval of its in-house developed recombinant protein COVID-19 vaccine SKYCovione (GBP510), in its home market of South Korea, two years after it began development. Strong support from the domestic government and international cooperation helped pave the way.

SKYCovione
SKYCovione Targets Low-Income Countries With Low Vaccination Rates • Source: SK Bioscience

As widely expected, SK Bioscience has become the first South Korean firm to get approval of an in-house developed COVID-19 vaccine. The Ministry of Food and Drug Safety (MFDS) in its home market gave the nod to SKYCovione (GBP510), on condition that data from a final clinical trial be submitted when available.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

More from Focus On Asia